Toggle navigation
Home
Search
Services
Blog
Contact
About
Production of A Recombinant H5 N1 Vaccine for Phase 1
Smith, Gail
Protein Sciences Corporation, Meriden, CT, United States
Search 21 grants from Gail Smith
Search grants from Protein Sciences Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Localized delivery of glycosaminoclycan ethers for the treatment of radiation-induced proctitis
Extensions of an Automated Algorithm to Examine CPR Compliance on and off Study
Activation of Macrophages in Human Autoimmune Diseases
Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)
Toxoplasmosis and Hoarding
Recently added grants:
Injectable Biomaterial for Treating Hypoplastic Left Heart Syndrome
A novel pathway of Th17/Th2 induction: The role of cAMP signaling in DC
Recovery Management Checkup for Primary Care (RMC-PC) vs. Screening Brief Intervention and Referral to Treatment (SBIRT) Experiment
Mechanisms of APP and APLP2 function at synapses
Race/Ethnic Differences in Life Course Exposure to Death: Consequences for Health
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI085333-002
Application #
2830748
Study Section
Project Start
1997-12-19
Project End
1998-12-18
Budget Start
1998-06-16
Budget End
1998-04-18
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost
Institution
Name
Protein Sciences Corporation
Department
Type
DUNS #
City
Meriden
State
CT
Country
United States
Zip Code
06450
Related projects
NIH 1998
N01 AI
Production of A Recombinant H5 N1 Vaccine for Phase 1
Smith, Gail / Protein Sciences Corporation
NIH 1998
N01 AI
Production of A Recombinant H5 N1 Vaccine for Phase 1
Smith, Gail / Protein Sciences Corporation
Comments
Be the first to comment on this grant